Cited by 374Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancerColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

Open access

Xiao, Yanping, Freeman, Gordon J.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-14-1397PMC PMC4295637

Open this paper in CoChat — free account

Abstract

Summary: The microsatellite instable (MSI) subset of colorectal cancer exhibits an active Th1/CTL immune microenvironment, probably due to recognition of a high number of tumor neoantigens. However, the high expression of checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, and IDO in MSI colorectal cancer distinguishes MSI from microsatellite stable colorectal cancer and creates an immunosuppressive microenvironment that may help MSI tumors evade immune destruction by the infiltrating immune cells. Though colorectal cancer does not have a good response rate to PD-1 pathway immunotherapy, these results suggest that the MSI subset of colorectal cancer is a particularly good candidate for checkpoint immunotherapy. Cancer Discov; 5(1); 16–8. ©2015 AACR. See related article by Llosa et al., p. 43

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-1397

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citation
Lynch Syndrome Patients with Limited Family History Identified in a Laboratory Setting: A Descriptive Study
Landon, M., Saam, J. R., Brown, K. L., Moyes, K., Evans, B. A., & WENSTRUP, R. J. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,943
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M. F., Giovannucci, E. L., & Fuchs, C. S. (2008) · Gut · doi:10.1136/gut.2008.155473 · Cited by 772
Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma
Smyrk, T. C., Watson, P. A., Kaul, K. L., & Lynch, H. T. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12 · Cited by 522
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 491
Fusobacterium in Colonic Flora and Molecular Features of Colorectal Carcinoma
Tahara, T., Yamamoto, E., Suzuki, H., Maruyama, R., Chung, W., Garriga, J., Jelinek, J., Yamano, H.-O., Sugai, T., An, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1865 · Cited by 465
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Lochhead, P. J., Kuchiba, A., Imamura, Y., Liao, X., Yamauchi, M., Nishihara, R., Qian, Z. R., Morikawa, T., Shen, J., Meyerhardt, J. A., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt173 · Cited by 442

Show all 11 references

Sorted by citations

Items 101–200 of 374

Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer
Mohan, H. M., Ryan, É. J., Balasubramanian, I., Kennelly, R. P., Geraghty, R., Sclafani, F., Fennelly, D. W., McDermott, R., Ryan, É. J., O’Donoghue, D. P., et al. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.05.013 · Cited by 56
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies
Alvi, M. A., Loughrey, M. B., Dunne, P. D., McQuaid, S., Turkington, R. C., Fuchs, M.-A., McGready, C., Bingham, V., Pang, B., Moore, W., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.168 · Cited by 58
A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I–III colon cancer
Zhou, R., Zeng, D., Zhang, J., Sun, H., Wu, J., Li, N., Li, L., Shi, M., Bin, J., Liao, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.043 · Cited by 54
Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies
Wang, Y., Lu, K., Yang, X., Xu, S., Chu, H., & Fang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1678907 · Cited by 57
Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas
Fennell, L., Dumenil, T. D., Wockner, L. F., Härtel, G., Nones, K., Bond, C., Borowsky, J., Liu, C., McKeone, D., Bowdler, L. M., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.002 · Cited by 54
Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile
Strasser, K., Birnleitner, H., Beer, A., Pils, D., Gerner, M. C., Schmetterer, K. G., Bachleitner‐Hofmann, T., Stift, A., Bergmann, M. M., & Oehler, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1537693 · Cited by 54
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy
Chen, T.-W., Huang, K. C., Chiang, S., Chen, W. T., Ke, T., & Chao, K. S. C. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02874-7 · Cited by 53
Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Gastric Carcinomas With Lymphoid Stroma
Hissong, E. M., Ramrattan, G., Zhang, P., Zhou, X. K., Young, G. Q., Klimstra, D. S., Shia, J., Fernandes, H., & Yantiss, R. K. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001018 · Cited by 50
PIPKI γ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling
Xue, J., Ge, X., Zhao, W., Xue, L., Dai, C., Lin, F., & Peng, W. (2019) · Journal of Immunology Research · doi:10.1155/2019/3690561 · Cited by 49
Immunotherapy in human colorectal cancer: Challenges and prospective
Sun, X., Suo, J., & Yan, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6362 · Cited by 50
Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma—New Therapeutic Targets
Mitteldorf, C., Berisha, A., Pfaltz, M. C., Broekaert, S. M. C., Schön, M. P., Kerl, K., & Kempf, W. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000851 · Cited by 47
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
Zou, X.-L., Li, X., Ke, H., Zhang, G., Tang, Q., Yuan, J., Zhou, C.-J., Zhang, J., Zhang, R., & Chen, W.-Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689076 · Cited by 48
Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research
Inoue, A., Deem, A. K., Kopetz, S., Heffernan, T. P., Draetta, G. F., & Carugo, A. (2019) · Cancers · doi:10.3390/cancers11091321 · Cited by 46
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
Kabiljo, J., Harpain, F., Carotta, S., & Bergmann, M. M. (2019) · Cancers · doi:10.3390/cancers12010079 · Cited by 48
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 46
Prediction of biological behavior and prognosis of colorectal cancer patients by tumor MSI/MMR in the Chinese population
Yan, W., Hu, J. Y., Xie, L., Cheng, L., Yang, M., Li, L., Shi, J., Liu, B., & Qian, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s117089 · Cited by 47
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Rawla, P., Barsouk, A. A., Hadjinicolaou, A. V., & Barsouk, A. (2019) · Medical Sciences · doi:10.3390/medsci7080083 · Cited by 46
A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients
Zhu, X., Tian, X., Ji, L., Zhang, X., Cao, Y., Shen, C., Hu, Y., Wong, J. W. H., Fang, J.-Y., Hong, J., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00142-x · Cited by 41
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers
Kim, J. H., Seo, M.-K., Lee, J. A., Yoo, S., Oh, H. J., Kang, H., Cho, N., Bae, J. M., Kang, G. H., & Kim, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003414 · Cited by 45
HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers
Chen, B., Li, L., Li, M., & Wang, X. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00534-4 · Cited by 41
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Franzese, O., & Graziani, G. (2022) · Cancers · doi:10.3390/cancers14225633 · Cited by 44
Periostin deficiency reduces PD-1+ tumor-associated macrophage infiltration and enhances anti-PD-1 efficacy in colorectal cancer
Wei, T., Wang, K., Liu, S., Fang, Y., Hong, Z., Liu, Y., Zhang, H., Yang, C. J., Ouyang, G., & Wu, T. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112090 · Cited by 42
BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations
Deihimi, S., Lev, A., Slifker, M. J., Shagisultanova, E. I., Xu, Q., Jung, K., Vijayvergia, N., Ross, E. A., Xiu, J., Swensen, J. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18098 · Cited by 42
Interplay between DNA damage repair and apoptosis shapes cancer evolution through aneuploidy and microsatellite instability
Auslander, N., Wolf, Y. I., & Koonin, E. V. (2020) · Nature Communications · doi:10.1038/s41467-020-15094-2 · Cited by 41
The importance of being a regulatory T cell in pregnancy
Clark, D. A. (2016) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2016.04.288 · Cited by 39
Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers
Zhang, P., Liu, M., Cui, Y., Zheng, P., & Liu, Y. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa180 · Cited by 39
Cellular Signaling Pathways Implicated in Metastasis of Colorectal Cancer and the Associated Targeted Agents
Liu, X., Ji, Q., Fan, Z., & Li, Q. (2015) · Future Oncology · doi:10.2217/fon.15.235 · Cited by 38
PD ‐1 and PD‐L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma
Mitteldorf, C., Berisha, A., Tronnier, M., Pfaltz, M. C., & Kempf, W. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.12973 · Cited by 38
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression
Martínez‐Ciarpaglini, C., Oltra, S. S., Roselló, S., Roda, D., Mongort, C., Carrasco, F., González, J., Gómez, F. J. S., Tarazona, N., Huerta, M., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0124-5 · Cited by 38
Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis
Liu, J., Cho, Y. B., Hong, H. K., Wu, S., Ebert, P. J., Bray, S. M., Wong, S. S., Ting, J. C., Calley, J. N., Whittington, C. F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67842-5 · Cited by 38
From APC to the genetics of hereditary and familial colon cancer syndromes
Olkinuora, A. P., Peltomäki, P., Aaltonen, L. A., & Rajamäki, K. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab208 · Cited by 41
Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment
Li, M., Liu, Z., & Wang, X. (2018) · Journal of Oncology · doi:10.1155/2018/3979527 · Cited by 37
Small RNA expression from viruses, bacteria and human miRNAs in colon cancer tissue and its association with microsatellite instability and tumor location
Mjelle, R., Sjursen, W., Thommesen, L., Sætrom, P., & Hofsli, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5330-0 · Cited by 35
Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy
Li, Y., Yang, C. G., Liu, Z., Du, S., Can, S., Zhang, H., Zhang, L., Huang, X., Xiao, Z., Li, X., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01462-z · Cited by 34
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
Masucci, G. V., Cesano, A., Eggermont, A. M. M., Fox, B. A., Wang, E., Marincola, F. M., Ciliberto, G., Dobbin, K. K., Puzanov, I. J., Taube, J. M., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1325-2 · Cited by 36
Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
Murakami, D., Matsuda, K., Iwamoto, H., Mitani, Y., Mizumoto, Y., Nakamura, Y., Matsuzaki, I., Iwamoto, R., Takahashi, Y., Kojima, F., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265908 · Cited by 36
Quantifying the limits of CAR T-cell delivery in mice and men
Brown, L., Gaffney, E. A., Ager, A., Wagg, J., & Coles, M. C. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2020.1013 · Cited by 35
Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer
Echterdiek, F., Janikovits, J., Staffa, L., Müller, M., Lahrmann, B., Frühschütz, M., Hartog, B., Nelius, N., Benner, A., Tariverdian, M., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1075692 · Cited by 34
Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells
Fragale, A., Romagnoli, G., Licursi, V., Buoncervello, M., Vecchio, G. D., Giuliani, C., Parlato, S., Leone, C., Angelis, M. D., Canini, I., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0080 · Cited by 33
Immunogenic chemotherapy in two mouse colon cancer models
Taniura, T., Iida, Y., Kotani, H., Ishitobi, K., Tajima, Y., & Harada, M. (2020) · Cancer Science · doi:10.1111/cas.14624 · Cited by 33
Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer
Luo, W., Dai, W., Li, Q., Mo, S., Han, L., Xiao, X., Gu, R., Xiang, W., Ye, L., Wang, R., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69808 · Cited by 34
PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1
Ho, H., Chou, T., Yang, S.-H., Jiang, J., Chen, W.-S., Chao, Y., & Teng, H. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02942-y · Cited by 31
Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy
Tsuchiya, T., Someya, M., Takada, Y., Hasegawa, T., Kitagawa, M., Fukushima, Y., Gocho, T., Hori, M., Nakata, K., Hirohashi, Y., et al. (2020) · Strahlentherapie und Onkologie · doi:10.1007/s00066-019-01571-1 · Cited by 32
Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas
Condelli, V., Calice, G., Cassano, A., Basso, M., Rodriquenz, M. G., Zupa, A., Maddalena, F., Crispo, F., Pietrafesa, M., Aieta, M., et al. (2021) · Cancers · doi:10.3390/cancers13010158 · Cited by 31
Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma
Asano, T., Ohishi, T., Takei, J., Nakamura, T., Nanamiya, R., Hosono, H., Tanaka, T., Sano, M., Harada, H., Kawada, M., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8124 · Cited by 30
Genomic Amplification and Functional Dependency of the Gamma Actin Gene ACTG1 in Uterine Cancer
Richter, C., Mayhew, D. L., Rennhack, J. P., So, J., Stover, E. H., Hwang, J. H., & Szczesna‐Cordary, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228690 · Cited by 30
Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer
Zheng, W., Wu, F., Fu, K., Sun, G., Sun, G., Li, X., Jiang, W., Cao, H., Wang, H., & Tang, W. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s301371 · Cited by 30
Immune checkpoints and cancer in the immunogenomics era
Park, R. M., Winnicki, M., Liu, E., & Chu, W. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely027 · Cited by 32
Polycythemia vera and essential thrombocythemia in young patients.
Frezzato, M., Ruggeri, M., Castaman, G., & Rodeghiero, F. (1993) · PubMed · Cited by 30
Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.
del Arco, C. D., Ortega, L. M., Muñoz, L. E., Heras, S. G. G. D. L., & Fernández‐Aceñero, M. J. (2021) · PubMed · doi:10.14670/hh-18-309 · Cited by 29
PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
Zhang, Y., Chen, X., Mo, S., Ma, H., Lu, Z., Yu, S., & Chen, J. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.259 · Cited by 31
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
Cona, M. S., Lecchi, M., Cresta, S., Damian, S., Vecchio, M. D., Necchi, A., Poggi, M. M., Raggi, D., Randon, G., Ratta, R., et al. (2019) · Cancers · doi:10.3390/cancers11020223 · Cited by 28
TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Lin, A., Zhang, H., Meng, H., Deng, Z., Gu, T., Luo, P., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667875 · Cited by 27
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
Sinicrope, F. A., Ou, F., Arnold, D., Peters, W. R., Behrens, R. J., Lieu, C. H., Matin, K., Cohen, D. J., Potter, S. L. P., Nixon, A. B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2507874 · Cited by 30
Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks
Simmons, A. J., Scurrah, C. R., McKinley, E. T., Herring, C. A., Irish, J. M., Washington, M. K., Coffey, R. J., & Lau, K. S. (2016) · Science Signaling · doi:10.1126/scisignal.aah4413 · Cited by 26
Recurrent somatic mutations reveal new insights into consequences of mutagenic processes in cancer
Stobbe, M. D., Thun, G. A., Diéguez-Docampo, A., Oliva, M., Whalley, J. P., Raineri, E., & Gut, I. G. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007496 · Cited by 25
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
Roth, M., & Das, S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1851201 · Cited by 28
Medical Oncologists’ Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care
Gray, S. W., Kim, B. B., Sholl, L. M., Cronin, A. M., Parikh, A. R., Klabunde, C. N., Kahn, K. L., Haggstrom, D. A., & Keating, N. L. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.016659 · Cited by 26
NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel
Xu, J. Z., Ren, X., Guo, T., Sun, X., Chen, X., Patterson, L. H., Li, H., & Zhang, J. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105034 · Cited by 25
Development and validation of prognostic model based on the analysis of autophagy-related genes in colon cancer
Wang, Y., Lin, K., Xu, T., Wang, L., Fu, L., Zhang, G., Ai, J., Jiao, Y., Zhu, R., Han, X., et al. (2021) · Aging · doi:10.18632/aging.203352 · Cited by 25
Challenges and exploration for immunotherapies targeting cold colorectal cancer
Li, D., Tang, Y., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i1.55 · Cited by 27
Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas
On behalf of investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort, Clendenning, M., Huang, A., Jayasekara, H., Lorans, M., Preston, S., O’Callaghan, N., Pope, B. J., Macrae, F., Winship, I., et al. (2017) · Familial Cancer · doi:10.1007/s10689-017-0013-y · Cited by 25
Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
Zhang, Y., Sun, Z., Mao, X., Wu, H., Luo, F., Wu, X., Zhou, L., Qin, J., Zhao, L., & Bai, C. (2017) · Oncotarget · doi:10.18632/oncotarget.20241 · Cited by 25
Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value
He, W., Hu, W., Kong, P., Yang, L., Yang, Y., Xie, Q., Jiang, C., Yin, C., Qiu, H., Zhang, B., et al. (2018) · Journal of Cancer · doi:10.7150/jca.26669 · Cited by 25
Advances in therapeutic application of CRISPR-Cas9
Sun, J., Wang, J., Zheng, D., & Hu, X. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz031 · Cited by 25
Changing the course of pancreatic cancer – Focus on recent translational advances
Javle, M. M., Golan, T., & Maitra, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.004 · Cited by 24
Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era
Shimozaki, K., Nakayama, I., Hirota, T., & Yamaguchi, K. (2023) · Cells · doi:10.3390/cells12071049 · Cited by 25
Targeted therapy for advanced gastric cancer: A review of current status and future prospects
Kanat, Ö., O’Neil, B. H., & Shahda, S. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i12.401 · Cited by 24
Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers
Yang, L., He, W., Kong, P., Jiang, C., Yang, Q., Xie, Q., & Xia, L. (2017) · BMC Cancer · doi:10.1186/s12885-017-3862-8 · Cited by 23
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
Ciardiello, D., Maiorano, B. A., Parente, P., Rodriquenz, M. G., Latiano, T. P., Chiarazzo, C., Pazienza, V., Guerrera, L. P., Amoruso, B., Normanno, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020820 · Cited by 23
Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment
Begum, R., & Martin, S. A. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.11.026 · Cited by 25
Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression
Zwinsová, B., Петров, В. А., Hrivňáková, M., Smatana, S., Micenková, L., Kazdová, N., Popovici, V. C., Hrstka, R., Šefr, R., Bencsiková, B., et al. (2021) · Cancers · doi:10.3390/cancers13194799 · Cited by 23
Intestinal stents: Structure, functionalization and advanced engineering innovation
Feng, Y., Chen, Y., Chen, Y., He, X., Khan, Y., Hu, H., Lan, P., Li, Y., Wang, X., Li, G., et al. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212810 · Cited by 21
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Moutafi, M. K., Koliou, G.-A., Papaxoinis, G., Economopoulou, P., Kotsantis, I., Gkotzamanidou, M. A., Anastasiou, Μ., Pectasides, D. G., Kyrodimos, E., Delides, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0051 · Cited by 27
The PD ‐1 expressing immune phenotype of T cell exhaustion is prominent in the ‘immunoreactive’ microenvironment of colorectal carcinoma
Prall, F., & Hühns, M. (2017) · Histopathology · doi:10.1111/his.13231 · Cited by 22
Tumour neoantigen heterogeneity thresholds provide a time window for combination immunotherapy
Aguadé‐Gorgorió, G., & Solé, R. V. (2020) · Journal of The Royal Society Interface · doi:10.1098/rsif.2020.0736 · Cited by 23
Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer
Roxburgh, C. S. D., Shia, J., Vakiani, E., Daniel, T. D., & Weiser, M. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1435227 · Cited by 21
Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations
Porkka, N., Valo, S., Nieminen, T. T., Olkinuora, A. P., Mäki‐Nevala, S., Eldfors, S., & Peltomäki, P. (2017) · Oncotarget · doi:10.18632/oncotarget.22445 · Cited by 21
Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status
Valentini, A., Pinto, F. D., Coletta, S., Guerra, V., Armentano, R., & Caruso, M. L. (2019) · Oncology Letters · doi:10.3892/ol.2019.10513 · Cited by 21
The current status and prospect of immunotherapy in colorectal cancer
Shu, Y., & Zheng, S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03235-0 · Cited by 21
Deep profiling of gene expression across 18 human cancers
Qiu, W., Dincer, A. B., Janizek, J. D., Çelik, S., Pittet, M. J., Naxerova, K., & Lee, S. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01290-8 · Cited by 25
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
Jin, C., Zhu, X., Huang, X., Gong, T., Wei, Z., & You, J. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0134 · Cited by 19
Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening
Zhang, J., Shen, L., & Johnston, S. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-35673-0 · Cited by 19
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 20
Molecular subtyping improves prognostication of Stage 2 colorectal cancer
Purcell, R. V., Schmeier, S., Lau, Y. C., Pearson, J. F., & Frizelle, F. A. (2019) · BMC Cancer · doi:10.1186/s12885-019-6327-4 · Cited by 19
Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells
Kobori, T., Tanaka, C., Tameishi, M., Urashima, Y., Ito, T., & Obata, T. (2021) · Pharmaceuticals · doi:10.3390/ph14090864 · Cited by 19
Programmed death-ligand 1 expression in rectal cancer
Jomrich, G., Silberhumer, G. R., Marian, B., Beer, A., & Müllauer, L. (2016) · European surgery. Supplement/European surgery · doi:10.1007/s10353-016-0447-8 · Cited by 19
Auranofin loaded silk fibroin nanoparticles for colorectal cancer treatment
Pérez-Lloret, M., Reidy, E., Pérez, A. A. L., Marchal, J. A., Lens, P. N. L., Ryan, A. E., & Erxleben, A. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01719-2 · Cited by 18
High expression of CCNB1 driven by ncRNAs is associated with a poor prognosis and tumor immune infiltration in breast cancer
Fu, H., Li, K., Wang, S., & Li, Y. (2022) · Aging · doi:10.18632/aging.204253 · Cited by 18
Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis
Jou, E., Rodríguez‐Rodríguez, N., & McKenzie, A. N. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981479 · Cited by 19
Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis
Kang, H. J., Lee, I., Park, Y.-S., Ho, W. J., Sohn, D., Ahn, J.-Y., Yook, J. H., & Kim, B. S. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5284-2 · Cited by 18
The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers
Han, S., Chok, A. Y., Peh, D. Y. Y., Ho, J. Z.-M., Tan, E., Koo, S., Tan, I. B., & Ong, J. C.-A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.933475 · Cited by 18
Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression
Sudoyo, A. W., Kurniawan, A. N., Kusumo, G. D., Putra, T. P., Rexana, F., Yunus, M., Budiyati, A. D., Kurniawan, D., Utama, A., & Utomo, A. R. H. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.11.3421 · Cited by 17
Pan-Cancer Analysis of Voltage-Dependent Anion Channel (VDAC1) as a Cancer Therapeutic Target or Diagnostic Biomarker
Wang, Z.-T., Cheng, Y., Song, Z., & Zhao, R. (2022) · Disease Markers · doi:10.1155/2022/5946110 · Cited by 17
Is tumor mutational burden predictive of response to immunotherapy?Preprint
Gurjao, C., Tsukrov, D. I., Imakaev, M., Luquette, L. J., & Mirny, L. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.03.260265 · Cited by 17
A Bioinformatics Evaluation of the Role of Dual-Specificity Tyrosine-Regulated Kinases in Colorectal Cancer
Laham, A. J., El‐Awady, R., Lebrun, J. J., & Saber-Ayad, M. M. (2022) · Cancers · doi:10.3390/cancers14082034 · Cited by 16
The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability
Tang, J., Wu, J., Liu, D., Luo, J., Wu, X., Pan, Z., Ding, P., & Li, Y. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1488566 · Cited by 15
Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients
Wang, Y., Dong, J., Quan, Q., Liu, S., Chen, X., Cai, X., Qiu, H., Zhang, B., & Guo, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.581051 · Cited by 16
Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
Xie, H., Wang, W., Qi, W.-C., Jin, W., & Xia, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661115 · Cited by 17

Authors: Xiao, Y., & Freeman, G. J.
Affiliations: Harvard University (US)
Corresponding author: Freeman, Gordon J.
ORCID: Freeman, Gordon J.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-01-01
Volume: 5
Issue: 1
Pages: 16-18
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-14-1397
PMC: PMC4295637
OpenAlex: W2042797183
Cited by: 368
References: 11
Citations by year: 2026: 5 · 2025: 13 · 2024: 17 · 2023: 26 · 2022: 54 · 2021: 44 · 2020: 36 · 2019: 46 · 2018: 35 · 2017: 40 · 2016: 37 · 2015: 14
FWCI: 18.34
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Public Health Service (HHSN272201100018C)
National Cancer Institute (U54CA163125, P50CA101942)
National Institute of Allergy and Infectious Diseases (HHSN272201100018C, P01AI056299)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: microsatellite instability, colorectal cancer, immune checkpoint blockade, PD-1, PD-L1, CTLA-4, LAG-3, IDO, tumor immune microenvironment, neoantigens, immunosuppression, immunotherapy response
MeSH terms: Colonic Neoplasms, Humans, Microsatellite Instability, Tumor Microenvironment, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks